Study Design and Participants
schizophrenia
This study is a 12-week, 2-center, parallel RCT evaluating the therapeutic effects of MPGT compared with TAU in patients with schizophrenia. Patients and raters were masked to MPGT or TAU randomization. The trial protocol can be found in Participants were enrolled at the Peking University Sixth Hospital, Beijing, China, and the Second People’s Hospital of Guizhou Province, Guiyang, China, between March 2020 and March 2022. All participants were male Chinese Han inpatients aged 18 to 60 years who met the The protocols of this study were approved by the Medical Ethical Committee of the Sixth Hospital of Peking University and the Medical Ethical Committee of the Second People’s Hospital of Guizhou Province. Written informed consent from all participants or their guardians was obtained. The RCT conformed to the Consolidated Standards of Reporting Trials (